BioCentury
ARTICLE | Clinical News

Shire's intrathecal ERT misses in MPS II trial

December 22, 2017 12:17 AM UTC

Shire plc (LSE:SHP; NASDAQ:SHPG) reported top-line data showing that intrathecal idursulfase (SHP609; formerly HGT-2310) missed the primary endpoint in the Phase II/III HGT-HIT-094 trial to treat pediatric patients with mucopolysaccharidosis II (MPS II, Hunter syndrome) and cognitive impairment. The product is an intrathecal formulation of idursulfase, an iduronate-2-sulfatase enzyme.

Shire markets an IV formulation of idursulfase as Elaprase to treat MPS II in over 70 countries, including EU countries and the U.S...

BCIQ Company Profiles

Shire plc